Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Equity (2019 - 2025)

Historic Return on Equity for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to 0.64%.

  • Allogene Therapeutics' Return on Equity fell 700.0% to 0.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64%, marking a year-over-year decrease of 700.0%. This contributed to the annual value of 0.55% for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Allogene Therapeutics' Return on Equity stood at 0.64%, which was down 700.0% from 0.64% recorded in Q2 2025.
  • Allogene Therapeutics' Return on Equity's 5-year high stood at 0.19% during Q4 2021, with a 5-year trough of 0.64% in Q2 2025.
  • In the last 5 years, Allogene Therapeutics' Return on Equity had a median value of 0.55% in 2024 and averaged 0.45%.
  • As far as peak fluctuations go, Allogene Therapeutics' Return on Equity soared by 1200bps in 2021, and later crashed by -3000bps in 2023.
  • Over the past 5 years, Allogene Therapeutics' Return on Equity (Quarter) stood at 0.19% in 2021, then plummeted by -148bps to 0.47% in 2022, then decreased by -21bps to 0.57% in 2023, then dropped by -1bps to 0.57% in 2024, then decreased by -11bps to 0.64% in 2025.
  • Its Return on Equity was 0.64% in Q3 2025, compared to 0.64% in Q2 2025 and 0.62% in Q1 2025.